To the effect of IDC products on dark spots on face and neck.
Phase 4
Completed
- Conditions
- Health Condition 1: null- hyper pigmentation/dark spots of the face and neck.
- Registration Number
- CTRI/2012/02/002434
- Lead Sponsor
- Glenmark Pharmaceuticals Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Subjects with hyper pigmentation/dark spots of the face and neck.
Age group: 30 years and above
Willing to restrain from prolonged exposure to the sun for the length of the study
Available for the entire duration of the study
Exclusion Criteria
Hypersensitivity to any ingredients
Pregnant and lactating women.
Subjects who are already applying anti-aging, skin lightening or AHA (Alpha hydroxy acids) based or retinol based cosmetics or have applied any of these in the last 3 months.
Subjects with dermatological disorder of face that may interfere with study evaluation.
Subjects who have undergone any surgical treatment of the face.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement in spots darkenss MASI scoring <br/ ><br>Physicians Global Assessment Grade for improvement in complexion / dark spots on the face and neck <br/ ><br>Patients Global Assessment Grade for improvement in complexion / dark spots on the face and neck <br/ ><br>Quality of life Questionnaire <br/ ><br>Patient Satisfaction Questionnaire <br/ ><br>Timepoint: 12 weeks
- Secondary Outcome Measures
Name Time Method ILTimepoint: NI